ArticleJournal of Crohn's & colitis2025
Spatiotemporal analysis of Crohn's disease reveals PECAM2 signaling at the basis of the inflammation-to-fibrosis transition.
Article in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatial Immunology in Translation: Linking Immune Organisation to Therapeutic Outcome.Medical sciences (Basel, Switzerland) · 2026Review
- mFrontiers in immunology · 2026Review
- Elucidating the role of IgA plasma cells and PECAM1-CD38 interaction in intestinal fibrosis: a single-cell RNA sequencing analysis in Crohn's disease.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
BACKGROUND AND
aimsCrohn's disease (CD) is a chronic inflammatory disease of the bowel, often complicated by fibrotic strictures, for which medical treatment is lacking, and surgery is commonly required. The mechanisms underlying the progression from chronic inflammation to fibrosis are not yet defined. We aim to unravel CD pathogenesis using a cutting-edge computational pipeline combining several available tools.
methodsSpatial transcriptomics was performed on 13 surgical specimens, including inflamed and fibrotic CD tissues and healthy controls. The resulting spatial data were integrated with single-cell RNA sequencing to trace the cellular and molecular transitions from healthy intestine to fibrotic tissue. Ligand-receptor interaction and pseudotime analyses were employed to infer dynamic cell-cell communication networks and lineage trajectories. Key computational findings were validated through immunostaining in an independent cohort of CD patients. Finally, the therapeutic relevance of the identified target was evaluated in a TNBS-induced chronic colitis mouse model upon CD38 inhibitor administration.
resultsWe demonstrated that intestinal cytoarchitecture was rearranged while chronic inflammation progressed. CD-associated fibrosis evolved within the mesenchymal compartment, driven by PECAM2 signaling through the PECAM1-CD38 interaction. In parallel, ApoA signaling, particularly the APOA1-ABCA interaction, emerged as relevant for maintaining epithelial and stromal homeostasis, while its downregulation was associated with fibrosis development. Moreover, inhibition of CD38 signaling effectively reduced colitis symptoms and colon thickening in the experimental TNBS-induced model of chronic inflammation.
conclusionsOur results provide insights into CD38-driven fibrosis and indicate that blockade of PECAM2 signaling could reduce the development of strictures in patients with CD, potentially offering a new treatment target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.